A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
Recruiting now · Phase 4
Conditions studied: SARS-CoV-2
In brief
The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Key facts
- Study ID
- NCT06585241
- Run by
- ModernaTX, Inc.
- People needed
- 1144
- Starts
- 2024-09-09
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2026-03-27
Who can join
Age: 1 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- CenExel — Atlanta, Georgia, United States (enrolling)
- CenExel — Decatur, Georgia, United States (enrolling)
- Velocity Clinical Research — Baton Rouge, Louisiana, United States (enrolling)
- Velocity Clinical Research — Gulfport, Mississippi, United States (enrolling)
- Velocity Clinical Research — Omaha, Nebraska, United States (enrolling)
- Richard Bennett - Clinical Research Partners — Richmond, Virginia, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.